EQRx, Inc., a pharmaceutical company, engages in developing medicines primarily for the treatment of oncology and immune-inflammatory diseases in the United States.
Company profile
Ticker
EQRX, EQRXW
Exchange
Website
CEO
Melanie I. Nallicheri
Employees
Location
Fiscal year end
Industry (SIC)
Former names
CM Life Sciences III Inc.
SEC CIK
Corporate docs
IRS number
861691173
EQRX stock data
Latest filings (excl ownership)
15-12G
Securities registration termination
20 Nov 23
EFFECT
Notice of effectiveness
20 Nov 23
EFFECT
Notice of effectiveness
20 Nov 23
EFFECT
Notice of effectiveness
20 Nov 23
POS AM
Prospectus update (post-effective amendment)
9 Nov 23
POS AM
Prospectus update (post-effective amendment)
9 Nov 23
S-8 POS
Registration of securities for employees (post-effective amendment)
9 Nov 23
POS AM
Prospectus update (post-effective amendment)
9 Nov 23
S-8 POS
Registration of securities for employees (post-effective amendment)
9 Nov 23
25-NSE
Exchange delisting
9 Nov 23
Latest ownership filings
SC 13G/A
ARCH Venture Fund X, L.P.
17 Nov 23
SC 13D/A
AH Bio Fund II, L.P.
17 Nov 23
SC 13D/A
Andreessen Horowitz Fund I, L.P.
15 Nov 23
SC 13D/A
Casdin Capital, LLC
15 Nov 23
4
Eli Casdin
14 Nov 23
4
Melanie Nallicheri
9 Nov 23
4
PAUL L BERNS
9 Nov 23
4
SAMUEL J. MERKSAMER
9 Nov 23
4
Sandra Horning
9 Nov 23
4
Dina Ciarimboli
9 Nov 23
Financial summary
Quarter (USD) | Sep 23 | Jun 23 | Mar 23 | Dec 22 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 22 | Dec 21 | |
---|---|---|---|
Revenue | |||
Cost of revenue | |||
Operating income | |||
Operating margin | |||
Net income | |||
Net profit margin | |||
Cash on hand | |||
Change in cash | |||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 316.31 mm | 316.31 mm | 316.31 mm | 316.31 mm | 316.31 mm | 316.31 mm |
Cash burn (monthly) | (no burn) | 56.86 mm | 33.85 mm | 32.99 mm | 20.64 mm | 27.51 mm |
Cash used (since last report) | n/a | 387.48 mm | 230.66 mm | 224.83 mm | 140.62 mm | 187.48 mm |
Cash remaining | n/a | -71.17 mm | 85.65 mm | 91.48 mm | 175.69 mm | 128.83 mm |
Runway (months of cash) | n/a | -1.3 | 2.5 | 2.8 | 8.5 | 4.7 |
Institutional ownership, Q3 2023
92.3% owned by funds/institutions
13F holders | Current |
---|---|
Total holders | 137 |
Opened positions | 32 |
Closed positions | 38 |
Increased positions | 43 |
Reduced positions | 32 |
13F shares | Current |
---|---|
Total value | 763.62 bn |
Total shares | 450.35 mm |
Total puts | 0.00 |
Total calls | 1.19 mm |
Total put/call ratio | – |
Largest owners | Shares | Value |
---|---|---|
GOOG Alphabet Inc - Ordinary Shares | 47.68 mm | $105.84 bn |
GV 2019 | 47.25 mm | $0.00 |
Casdin Capital | 39.53 mm | $87.75 bn |
Arch Venture | 36.34 mm | $80.66 bn |
ARCH Venture Fund X | 36.34 mm | $247.81 mm |
Vanguard | 33.26 mm | $73.85 bn |
FMR | 23.68 mm | $52.56 bn |
BLK Blackrock | 23.55 mm | $52.29 bn |
AH Bio Fund II | 19.19 mm | $166.78 mm |
Nextech Invest | 13.10 mm | $29.09 bn |
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
9 Nov 23 | Equity Partners Bio II, L.L.C. AH | Common Stock | Dispose U | Yes | No | 0 | 5,000,000 | 0.00 | 0 | |
9 Nov 23 | Equity Partners Bio II, L.L.C. AH | Common Stock | Dispose U | Yes | No | 0 | 11,433,677 | 0.00 | 0 | |
9 Nov 23 | Equity Partners Bio II, L.L.C. AH | Common Stock | Dispose U | Yes | No | 0 | 19,192,015 | 0.00 | 0 | |
9 Nov 23 | Equity Partners Bio II, L.L.C. AH | Common Stock | Dispose U | Yes | No | 0 | 17,438,465 | 0.00 | 0 | |
9 Nov 23 | Equity Partners Bio II, L.L.C. AH | Common Stock | Dispose U | Yes | No | 0 | 12,264 | 0.00 | 0 | |
9 Nov 23 | Equity Partners Bio II, L.L.C. AH | Earn-out Shares Common Stock | Dispose U | Yes | No | 0 | 1,574,510 | 0.00 | 0 | |
9 Nov 23 | Equity Partners Bio II, L.L.C. AH | Earn-out Shares Common Stock | Dispose U | Yes | No | 0 | 2,642,897 | 0.00 | 0 | |
9 Nov 23 | Equity Partners Bio II, L.L.C. AH | Earn-out Shares Common Stock | Dispose U | Yes | No | 0 | 2,401,418 | 0.00 | 0 | |
9 Nov 23 | Kathryn E Giusti | Earn-out Shares Common Stock | Sale back to company | Dispose D | No | No | 0 | 21,934 | 0.00 | 0 |
9 Nov 23 | Kathryn E Giusti | Stock Option Common Stock | Sale back to company | Dispose D | No | No | 4.95 | 101,010 | 500.00 k | 0 |